Abstract
purpose. The purpose of this study was to establish a rat dry eye model of corneal epithelial disorders by inducing improper tear dynamics and change in blink frequency. The protective effect of d-β-hydroxybutyrate (HBA) on the corneal epithelia was also investigated.
methods. A series of treatments were performed under continuous exposure to low-humidity airflow. Rats were placed on a jogging board (JB) made of a plastic pipe for 7.5 h/d, and, for 16.5 hours, they were placed in individual cages without JB treatment. The resultant changes in tear dynamics and corneal epithelial structure were then analyzed. Five days after the rats were exposed to the treatment, eyes that showed corneal fluorescein staining were examined, to investigate the effect of HBA, by administration of eye drops containing 80 mM HBA four times daily during JB treatment for 5 days.
results. Significant reductions in blink frequency, Schirmer score, and tear clearance were recorded during JB treatment in eyes that showed persistent punctate staining of almost one half of the corneal surface. The application of HBA-containing eye drops significantly reduced the punctate staining compared with the initial or phosphate-buffered saline–treated eyes.
conclusions. This rat dry eye model, established by repeated JB treatment in desiccating conditions, induced abnormal tear dynamics and superficial punctate keratopathy similar to that in humans. These findings suggest the potential clinical application of HBA in corneal surface epithelial disorders in patients with moderate to mild dry eye.
Dry eye represents various abnormal states involving the quality and/or quantity of the tear film and integrity of ocular surface cells.
1 2 Because dry eye consists of various clinical subtypes, its etiology is multifactorial. Much effort has been made to develop animal models of dry eye that mirror the etiologic factors of each clinical subtype, for the basic investigation of the pathophysiology of the disease. To induce abnormal changes in tear dynamics in experimental animals, various treatment methods have been attempted, such as pharmacologic blockade of cholinergic muscarinic receptors,
3 4 surgical excision of the lacrimal glands
5 6 or mechanical prevention of blinking.
7 However, these techniques are disadvantageous, because it is difficult to exclude the complex influence of surgical insult or the adverse effects of pharmacologic agents. Tear dynamics are maintained by a complicated arrangement of the blink frequency and tear production, drainage, and evaporation from the ocular surface.
8 Therefore, in addition to applying minimally invasive procedures, the key concept of developing an animal model of dry eye involves inducing the ocular surface disorder by deranging the balance of each factor essential in the maintenance of proper tear dynamics. This strategy would further the understanding of multiple pathophysiologies and the development of new treatments against dry eye.
d-β-Hydroxybutyrate (HBA) is a ketone body produced by hepatocytes and astrocytes through the degradation of long-chain fatty acids.
9 10 It exists abundantly in human plasma and peripheral tissues, in which levels are maintained below 0.1 mM in the normal state.
10 The role of HBA as an alternative energy source during glucose starvation or hypoxia in the brain has been well investigated.
11 12 13 Recently, in vivo and in vitro evidence showed that HBA prevents neuronal damage after challenge from neurotoxins that inhibit dopaminergic neuron activity.
14 15 These findings suggest that HBA plays a therapeutic role in preventing neurodegenerative conditions such as Parkinson’s disease. In ocular surface disorders, we showed that topically applied HBA ameliorates the appearance of acute-phase corneal epithelial erosion through suppression of apoptosis in a tear fluid depletion–induced rat dry eye model.
16 The potency of 80 mM HBA was the same as for 20% serum, in which the efficacy of clinical application has been well proven.
17 18 19 These findings suggest that there is potential for the use of HBA in ophthalmic formulations for curing ocular surface epithelial disorders in patients with dry eye. However, the effect of HBA on mild to moderate types of dry eye has not been investigated.
The purpose of this study was to establish a rat dry eye model of superficial punctate keratopathy (SPK), a hallmark of corneal surface disorders of mild to moderate types of dry eye, and assessed the effect of HBA. For development of corneal surface disorders, we induced dysfunctions in tear dynamics by a novel treatment method, which was inspired by the evidence that visual tasking is accompanied by a change in tear dynamics, abnormal blink frequency, and symptoms of dry eye.
20 21 22 23 24
Female 8-week-old Sprague-Dawley rats (Tokyo Laboratory Animal Science, Tokyo, Japan) were used for this study. They were quarantined and acclimatized before the experiments for 1 week under standard conditions (SC) as follows: room temperature 23 ± 2°C, relative humidity of 60% ± 10%, alternating 12 hour light–dark cycle (8 AM to 8 PM), and water and food available ad libitum. All procedures were performed according to the ARVO statement for the Use of Animals in Ophthalmic and Vision Research.
Study Design.
For the investigation of changes in tear dynamics, we compared the blink frequency (n = 4), tear fluorescein clearance (n = 8), and Schirmer score (n = 16) within two groups: rats placed in desiccated conditions (DC) for the entire time with daily jogging board (JB) treatment (DC+JB) and those placed in DC for the entire time without JB treatment (DC). For the investigation of pathologic changes, we compared corneal epithelial fluorescein staining (n = 16), histopathological changes (n = 8–10), and barrier function (n = 10) within three groups: DC+JB, DC alone, and SC with 7.5 h/d JB treatment (SC+JB).
Dry Eye Treatment.
Desiccated Conditions.
JB Treatment.
In the DC+JB group, each measurement was performed immediately before, after, and at the end of the JB treatment, to determine the blink rate and tear fluorescein clearance, and the Schirmer test was performed before and at the end of the treatment. In the DC group, each measurement was performed at the same time, corresponding to before and at the end of the JB treatment for blink rate and tear fluorescein clearance and at the end for the Schirmer test. Nontreatment measurements were taken under SC.
We used a modified Schirmer test on the rats’ eyes to measure tear fluid secretion under topical anesthesia induced with a 0.4% oxybuprocaine hydrochloride solution (Santen Pharmaceutical, Osaka, Japan). After 3 minutes of anesthesia, a phenol red thread (Zone-Quick; Menicon, Nagoya, Japan) was placed on the temporal side of the lower eyelid margin for 1 minute. The length of the moistened area from the edge was then measured to within 1 mm.
Corneal Fluorescein Staining.
Corneal Epithelial Barrier Function.
Rats were anesthetized with pentobarbital sodium, and then 5 μL of 0.5% fluorescein sodium solution was instilled into the conjunctival sac. The eyes were kept closed with surgical tape for 10 minutes, and then the excess fluorescein was washed out with saline. The eyes were then held closed for an additional 20 minutes. The fluorescein intensity of the central cornea was measured with a slit lamp fluorophotometer (FL-500; Kowa, Tokyo, Japan) which was modified for rats. The fluorescence intensity was measured eight times, and the background mean fluorescence level was subtracted and averaged. The fluorescein penetrance was then expressed in terms of photon counts per millisecond.
Histopathologic Examination.
Microscopic Morphometry.
Scanning Electron Microscopy.
Corneas were fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) and postfixed with 1% osmium tetroxide in 0.1 M phosphate buffer. After dehydration in a graded series of ethanol, the specimens were freeze dried with t-butyl alcohol, sputter-coated with platinum, and examined by scanning electron microscopy (X-650; Hitachi, Tokyo, Japan).
Sodium HBA was synthesized by Ophtecs Co. (Osaka, Japan) and its purity was >99% when tested by HPLC analysis. For the ophthalmic solution, 80 mM of HBA (wt/vol) was formulated in PBS, and the osmolarity was adjusted with NaCl from 290 to 300 mOsM. We selected the absolute concentration of HBA on the basis of the results of our previous in vivo study.
16
A series of assessments were performed during our dry eye treatment schedule. Five days after the rats were exposed to dry eye treatment, eyes that showed fluorescein staining higher than grade 3 were used in the examination. Eyes with SPK were randomly selected for HBA eye drops or PBS as a control. Five microliters of eye drops were then given every 2 hours for 8 hours, during which the rats were placed on a JB. After starting the 5 days of application, we used corneal fluorescein staining (n = 9 to 11), morphometric analysis of the epithelia (n = 10 to 11), blink frequency analysis (n = 4), tear fluorescein clearance analysis (n = 16), and Schirmer scoring (n = 10) to evaluate the effect of HBA.
Blink Rate.
Tear Fluorescein Clearance.
Schirmer Test.
Corneal Fluorescein Staining.
Histopathological Examination.
Microscopic Morphometry.
Corneal Epithelial Barrier Function.
Effect on the Corneal Epithelia.
Effect on Tear Dynamics.
In this study, for the first time, a rat model of moderate dry eye was established by a novel treatment method: persistent strain by JB treatment in combination with exposure to an evaporative environment, which induces disordered tear dynamics and abnormal blink frequency. Recent progress in understanding the pathophysiology of dry eye has demonstrated that the pathogenic mechanism is not limited to dysfunction of the lacrimal apparatus but also involves external factors such as a dehydrating environment
27 28 29 30 and visual tasking,
23 24 31 32 which induce changes in tear dynamics and blink frequency. Thus, our treatment procedure could be applicable to the study of multiple pathophysiologies and lead to the development of new treatments for dry eye.
Blinking is necessary to provide a controlled environment that maintains the integrity of the ocular surface by proper formation of a tear film and support of the lacrimal pump system.
33 34 Various psychological factors and/or ocular conditions such as mental tension, eye irritation, ocular fatigue, or performance of visual tasks modify the frequency of blinking.
35 36 When rats were placed on the JB in DC, a reduction in the blink frequency was observed during repeated treatment. Vision and eye movement play a primary role in maintaining postural equilibrium, and the fixation of vision promotes postural stability.
37 38 During the time that the rats were settled on the JB, postural equilibrium was constantly disturbed, making continuous visual fixation necessary to promote postural stability. The visual performance necessary for visual display terminal use, driving a car, or reading is associated with a reduction in blinking.
23 32 39 Therefore, the close relationship between postural equilibrium and visual performance may play a role in the mechanism responsible for the reduction in the blink frequency observed during JB treatment.
In addition to the reduction in the blink frequency, decreases in the Schirmer score and tear clearance were observed during JB treatment. We suspect that the reduction in tear production arose from the restrained response of the autonomous nervous system, which was elicited from persistent strain due to the adjustment of postural equilibrium. As a result of insufficient drainage with prolonged exposure of the ocular surface to an evaporative environment due to the decreased blink frequency and reduced tear production, tear clearance may have been significantly reduced. To clarify the mechanism responsible for the changes in tear dynamics during the dry eye treatment, physiologically visual and praxiologically based investigations are needed.
During our dry eye treatment, each factor used to determine the tear dynamics tear production, tear drainage, and evaporation from the ocular surface exhibited a declining trend for the healthy ocular surface. Thus, our results suggest that the simultaneous aggravation of these factors may be a critical risk factor in the pathogenesis of dry eye.
In animals and humans, there have been few investigation made into the relationship between the appearance of SPK and structural changes in the corneal epithelia. Our results showed that chronic SPK in the rat is accompanied by thinning and abnormal arrangement in the superficial layer including wing cells and in the basal columnar cell layer, poorly developed microvilli on surface cells and a reduction in barrier function. This indicates that the function and structure of the epithelia changed to an abnormal state and that this state was sustained during the dry eye treatment. The mature corneal epithelial cell layer is maintained by a balance between shedding superficial cells, cell proliferation and differentiation of the basal layer, and centripetal migration of cells from the limbus.
40 Taken together, our findings suggest that not only changes in surface cell integrity but also improper differentiation of the corneal epithelial cell layer are involved in the pathogenesis of SPK. The homeostasis of ocular surface cells is supported by proper interaction between nutrients, growth factors, cytokines, and retinoids presented in tear fluid.
1 41 42 43 44 For our dry eye condition, due to abnormal tear dynamics, prolonged imbalances in the composition, and the concentration of these factors may have been induced in a precorneal tear film that lead to the disturbance of corneal epithelial differentiation.
Our present study showed that topically applied HBA restores chronic SPK and thinning of the corneal epithelial cell layer. Previously, we also showed a similar effect of HBA on acute corneal epithelial degeneration due to thinning of the cell layer accompanied by extensive exfoliation in our rat dry eye model.
16 In neuronal tissues, HBA decreases the rate of cell death in Alzheimer’s and Parkinson’s disease models
14 15 45 and plays a role in preserving neuronal integrity during development.
46 Together the findings show that HBA does not affect the tear dynamics and may directly reverse epithelial cell degeneration, leading to the normalization of corneal epithelial differentiation under dry eye conditions. Recent investigations suggest that the ability of HBA to protect against neurotoxins, which cause dopaminergic neurodegeneration deficits reminiscent of Parkinson’s disease, is related to enhancing of the energy status
15 45 or suppression of free radical production,
14 by preserving the neuronal mitochondrial respiratory chain function. Although in dry eye little is known about the involvement of mitochondrial dysfunctions in corneal epitheliopathy, it is possible that this function plays a role in the protective effect of HBA.
In conclusion, we established a rat dry eye model of tear dynamic dysfunction that mirrors etiologic features in humans. The results of this study also suggest the potential usefulness of HBA for the clinical treatment of ocular surface epithelial disorders in patients with chronic symptoms of dry eye.
Submitted for publication November 18, 2004; revised March 10, 2005; accepted March 21, 2005.
Disclosure:
S. Nakamura, Ophtecs Corp. (E);
M. Shibuya, Ophtecs Corp. (E);
H. Nakashima, Ophtecs Corp. (E);
T. Imagawa, None;
M. Uehara, None;
K. Tsubota, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked “
advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Corresponding author: Shigeru Nakamura, Research Center, Ophtecs Corporation, 156-5, Kamiyoshidai, Toyooka, Hyogo, Japan 668-0831;
[email protected].
Table 1. Changes in Tear Dynamics after Dry Eye Treatment with HBA or PBS
Table 1. Changes in Tear Dynamics after Dry Eye Treatment with HBA or PBS
| Eyes (n) | PBS | d-β-Hydroxybutyrate |
Blink frequency (times/min) | 4 | 5.04 ± 0.58 | 5.41 ± 1.43 |
Fluorescein retained (% of instilled concentration) | 16 | 0.037 ± 0.008 | 0.034 ± 0.009 |
Schirmer score (mm/min) | 10 | 11.8 ± 0.79 | 11.8 ± 1.02 |
The authors thank Toyoaki Yoneda (Ophtecs Corp.) for his generous support.
HollyFJ, LempMA. Tear physiology and dry eyes. Surv Ophthalmol. 1977;22:69–87.
[CrossRef] [PubMed]TsengSC, TsubotaK. Important concepts for treating ocular surface and tear disorders. Am J Ophthalmol. 1997;124:825–835.
[CrossRef] [PubMed]BurgalassiS, PanichiL, ChetoniP, SaettoneMF, BoldriniE. Development of a simple dry eye model in the albino rabbit and evaluation of some tear substitutes. Ophthalmic Res. 1999;31:229–235.
[CrossRef] [PubMed]DursunD, WangM, MonroyD, LiDQ, LokeshwarBL, SternME, PflugfelderSC. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2002;43:632–638.
[PubMed]MaitchoukDY, BeuermanRW, OhtaT, SternM, VarnellRJ. Tear production after unilateral removal of the main lacrimal gland in squirrel monkeys. Arch Ophthalmol. 2000;118:246–252.
[CrossRef] [PubMed]FujiharaT, MurakamiT, FujitaH, NakamuraM, NakataK. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001;42:96–100.
[PubMed]FujiharaT, NaganoT, NakamuraM, ShirasawaE. Establishment of a rabbit short-term dry eye model. J Ocul Pharmacol Ther. 1995;11:503–508.
[CrossRef] [PubMed]TsubotaK. Tear dynamics and dry eye. Prog Retin Eye Res. 1998;17:565–596.
[CrossRef] [PubMed]GuzmanM, BlazquezC. Is there an astrocyte-neuron ketone body shuttle?. Trends Endocrinol Metab. 2001;12:169–173.
[CrossRef] [PubMed]RobinsonAM, WilliamsonDH. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol Rev. 1980;60:143–187.
[PubMed]OwenOE, MorganAP, KempHG, SullivanJM, HerreraMG, CahillGF, Jr. Brain metabolism during fasting. J Clin Invest. 1967;46:1589–1595.
[CrossRef] [PubMed]SuzukiM, SuzukiM, SatoK, DohiS, SatoT, MatsuuraA, HiraideA. Effect of beta-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats. Jpn J Pharmacol. 2001;87:143–150.
[CrossRef] [PubMed]SuzukiM, SuzukiM, KitamuraY, et al. Beta-hydroxybutyrate, a cerebral function improving agent, protects rat brain against ischemic damage caused by permanent and transient focal cerebral ischemia. Jpn J Pharmacol. 2002;89:36–43.
[CrossRef] [PubMed]KashiwayaY, TakeshimaT, MoriN, NakashimaK, ClarkeK, VeechRL. D-beta-hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s disease. Proc Natl Acad Sci. 2000;97:5440–5444.
[CrossRef] [PubMed]TieuK, PerierC, CaspersenC, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest. 2003;112:892–901.
[CrossRef] [PubMed]NakamuraS, ShibuyaM, SaitoY, et al. Protective effect of D-beta-hydroxybutyrate on corneal epithelia in dry eye conditions through suppression of apoptosis. Invest Ophthalmol Vis Sci. 2003;44:4682–4688.
[CrossRef] [PubMed]FoxRI, ChanR, MichelsonJB, BelmontJB, MichelsonPE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984;27:459–461.
[CrossRef] [PubMed]TsubotaK, HiguchiA. Serum application for the treatment of ocular surface disorders. Int Ophthalmol Clin. 2000;40:113–122.
[CrossRef] [PubMed]TananuvatN, DaniellM, SullivanLJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20:802–806.
[CrossRef] [PubMed]SommerHJ, JohnenJ, SchongenP, StolzeHH. Adaptation of the tear film to work in air-conditioned rooms (office-eye syndrome). Ger J Ophthalmol. 1994;3:406–408.
[PubMed]TodaI, FujishimaH, TsubotaK. Ocular fatigue is the major symptom of dry eye. Acta Ophthalmol (Copenh). 1993;71:347–352.
[CrossRef] [PubMed]ShimmuraS, ShimazakiJ, TsubotaK. Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. Cornea. 1999;18:408–411.
[CrossRef] [PubMed]TsubotaK, TodaI, NakamoriK. Poor illumination, VDTs, and desiccated eyes. Lancet. 1996;347:768–769.
TsubotaK, NakamoriK. Dry eyes and video display terminals. N Engl J Med. 1993;328:584.
KohS, WatanabeH, HosohataJ, et al. Diagnosing dry eye using a blue-free barrier filter. Am J Ophthalmol. 2003;136:513–519.
[CrossRef] [PubMed]WeibelER. Stereological principles for morphometry in electron microscopic cytology. Int Rev Cytol. 1969;26:235–302.
[PubMed]NilssonSE, AnderssonL. Contact lens wear in dry environments. Acta Ophthalmol (Copenh). 1986;64:221–225.
[PubMed]SchirraF, RuprechtKW. Dry eye An update on epidemiology, diagnosis, therapy and new concepts [in German]. Ophthalmologe. 2004;101:10–18.
[CrossRef] [PubMed]AlbietzJM. Dry eye: an update on clinical diagnosis, management and promising new treatments. Clin Exp Optom. 2001;84:4–18.
[CrossRef] [PubMed]MaruyamaK, YokoiN, TakamataA, KinoshitaS. Effect of environmental conditions on tear dynamics in soft contact lens wearers. Invest Ophthalmol Vis Sci. 2004;45:2563–2568.
[CrossRef] [PubMed]AcostaMC, GallarJ, BelmonteC. The influence of eye solutions on blinking and ocular comfort at rest and during work at video display terminals. Exp Eye Res. 1999;68:663–669.
[CrossRef] [PubMed]SchloteT, KadnerG, FreudenthalerN. Marked reduction and distinct patterns of eye blinking in patients with moderately dry eyes during video display terminal use. Graefes Arch Clin Exp Ophthalmol. 2004;242:306–312.
[CrossRef] [PubMed]HollyFJ. Formation and rupture of the tear film. Exp Eye Res. 1973;15:515–525.
[CrossRef] [PubMed]RolandoM, ZierhutM. The ocular surface and tear film and their dysfunction in dry eye disease. Surv Ophthalmol Suppl. 2001;45(suppl 2)S203–S210.
[CrossRef] PoultonEC, GregoryRL. Blinking during visual tracking. Q J Exp Physiol. 1952;4:57–65.
DoughtyMJ. Further assessment of gender- and blink pattern-related differences in the spontaneous eyeblink activity in primary gaze in young adult humans. Optom Vis Sci. 2002;79:439–447.
[CrossRef] [PubMed]SchulmannDL, GodfreyB, FisherAG. Effect of eye movements on dynamic equilibrium. Phys Ther. 1987;67:1054–1059.
[PubMed]RedfernMS, YardleyL, BronsteinAM. Visual influences on balance. J Anxiety Disord. 2001;15:81–94.
[CrossRef] [PubMed]GotoE, YagiY, MatsumotoY, TsubotaK. Impaired functional visual acuity of dry eye patients. Am J Ophthalmol. 2002;133:181–186.
[CrossRef] [PubMed]ThoftRA, FriendJ. The X, Y, Z hypothesis of corneal epithelial maintenance. Invest Ophthalmol Vis Sci. 1983;24:1442–1443.
[PubMed]WilsonSE. Lacrimal gland epidermal growth factor production and the ocular surface. Am J Ophthalmol. 1991;111:763–765.
[CrossRef] [PubMed]UbelsJL, FoleyKM, RismondoV. Retinol secretion by the lacrimal gland. Invest Ophthalmol Vis Sci. 1986;27:1261–1268.
[PubMed]van SettenGB. Basic fibroblast growth factor in human tear fluid: detection of another growth factor. Graefes Arch Clin Exp Ophthalmol. 1996;234:275–277.
[CrossRef] [PubMed]BartonK, MonroyDC, NavaA, PflugfelderSC. Inflammatory cytokines in the tears of patients with ocular rosacea. Ophthalmology. 1997;104:1868–1874.
[CrossRef] [PubMed]KweonGR, MarksJD, KrencikR, et al. Distinct mechanisms of neurodegeneration induced by chronic complex I inhibition in dopaminergic and non-dopaminergic cells. J Biol Chem. 2004;279:51783–51792.
[CrossRef] [PubMed]IzumiY, IshiiK, KatsukiH, BenzAM, ZorumskiCF. beta-Hydroxybutyrate fuels synaptic function during development: histological and physiological evidence in rat hippocampal slices. J Clin Invest. 1998;101:1121–1132.
[CrossRef] [PubMed]